This Article Full Text Full Text (PDF) Supplementary Data Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Datta, D. Articles by Pal, S. Search for Related Content PubMed PubMed Citation Articles by Datta, D. Articles by Pal, S.

Ras-induced Modulation of CXCL10 and Its Receptor Splice Variant CXCR3-B in MDA-MB-435 and MCF-7 Cells: Relevance for the Development of Human Breast Cancer

¹ Division of Nephrology and ² Transplantation Research Center, Children's Hospital Boston and Brigham and Women's Hospital; ³ Department of Pediatrics, Harvard Medical School, Boston, Massachusetts; and ⁴ Department of Surgery I, Molecular Oncology and Immunology, University of Wuerzburg, Wuerzburg, Germany

Requests for reprints: Soumitro Pal, Division of Nephrology, Children's Hospital, 300 Longwood Avenue, Boston, MA 02115. Phone: 617-919-2989; Fax: 617-730-0130; E-mail: soumitro.pal{at}childrens.harvard.edu.

Interactions between chemokines and chemokine receptors have been proposed recently to be of importance in the development and progression of cancer. Human breast cancer cells express the chemokine CXCL10 (IP-10) and also its receptor CXCR3. In this study, we have investigated the role of Ras activation in the regulation of CXCL10 and its receptor splice variant CXCR3-B in two human breast cancer cell lines MDA-MB-435 and MCF-7. In cotransfection assays, using a full-length CXCL10 promoter-luciferase construct, we found that the activated form of Ras, Ha-Ras(12V), promoted CXCL10 transcriptional activation. Ras significantly increased CXCL10 mRNA and protein expression as observed by real-time PCR, fluorescence-activated cell sorting analysis, and ELISA. Selective inhibition of Ha-Ras by small interfering RNA (siRNA) decreased CXCL10 mRNA expression in a dose-dependent manner. Further, using effector domain mutants of Ras, we found that Ras-induced overexpression of CXCL10 is mediated primarily through the Raf and phosphatidylinositol 3-kinase signaling pathways. We also observed that the expression of the splice variant CXCR3-B, known to inhibit cell proliferation, was significantly down-regulated by Ras. Selective inhibition of CXCR3-B using siRNA resulted in an increase in CXCL10-mediated breast cancer cell proliferation through G_i proteins and likely involving CXCR3-A. Finally, we observed intense expression of CXCL10 and CXCR3 in association with human breast cancer in situ, indicating that these observations may be of pathophysiologic significance. Together, these results suggest that activation of Ras plays a critical role in modulating the expression of both CXCL10 and CXCR3-B, which may have important consequences in the development of breast tumors through cancer cell proliferation. (Cancer Res 2006; 66(19): 9509-18)

This article has been cited by other articles:

				Y. Zhu, D. Vergote, C. Pardo, F. Noorbakhsh, J. C. McArthur, M. D. Hollenberg, C. M. Overall, and C. Power CXCR3 activation by lentivirus infection suppresses neuronal autophagy: neuroprotective effects of antiretroviral therapy FASEB J, September 1, 2009; 23(9): 2928 - 2941. [Abstract] [Full Text] [PDF]

				J. You, D. Mi, X. Zhou, L. Qiao, H. Zhang, X. Zhang, and L. Ye A Positive Feedback between Activated Extracellularly Regulated Kinase and Cyclooxygenase/Lipoxygenase Maintains Proliferation and Migration of Breast Cancer Cells Endocrinology, April 1, 2009; 150(4): 1607 - 1617. [Abstract] [Full Text] [PDF]

				X. Ma, K. Norsworthy, N. Kundu, W. H. Rodgers, P. A. Gimotty, O. Goloubeva, M. Lipsky, Y. Li, D. Holt, and A. Fulton CXCR3 expression is associated with poor survival in breast cancer and promotes metastasis in a murine model Mol. Cancer Ther., March 1, 2009; 8(3): 490 - 498. [Abstract] [Full Text] [PDF]

				D. Datta, A. G. Contreras, M. Grimm, A. M. Waaga-Gasser, D. M. Briscoe, and S. Pal Calcineurin Inhibitors Modulate CXCR3 Splice Variant Expression and Mediate Renal Cancer Progression J. Am. Soc. Nephrol., December 1, 2008; 19(12): 2437 - 2446. [Abstract] [Full Text] [PDF]

				J. P. Venables, R. Klinck, A. Bramard, L. Inkel, G. Dufresne-Martin, C. Koh, J. Gervais-Bird, E. Lapointe, U. Froehlich, M. Durand, et al. Identification of Alternative Splicing Markers for Breast Cancer Cancer Res., November 15, 2008; 68(22): 9525 - 9531. [Abstract] [Full Text] [PDF]

				A. Basu, A. G. Contreras, D. Datta, E. Flynn, L. Zeng, H. T. Cohen, D. M. Briscoe, and S. Pal Overexpression of Vascular Endothelial Growth Factor and the Development of Post-Transplantation Cancer Cancer Res., July 15, 2008; 68(14): 5689 - 5698. [Abstract] [Full Text] [PDF]

				M. L. Balestrieri, A. Balestrieri, F. P. Mancini, and C. Napoli Understanding the immunoangiostatic CXC chemokine network Cardiovasc Res, May 1, 2008; 78(2): 250 - 256. [Abstract] [Full Text] [PDF]

				D. Datta, O. Dormond, A. Basu, D. M. Briscoe, and S. Pal Heme oxygenase-1 modulates the expression of the anti-angiogenic chemokine CXCL-10 in renal tubular epithelial cells Am J Physiol Renal Physiol, October 1, 2007; 293(4): F1222 - F1230. [Abstract] [Full Text] [PDF]

				L. Lasagni, R. Grepin, B. Mazzinghi, E. Lazzeri, C. Meini, C. Sagrinati, F. Liotta, F. Frosali, E. Ronconi, N. Alain-Courtois, et al. PF-4/CXCL4 and CXCL4L1 exhibit distinct subcellular localization and a differentially regulated mechanism of secretion Blood, May 15, 2007; 109(10): 4127 - 4134. [Abstract] [Full Text] [PDF]

				A. Zipin-Roitman, T. Meshel, O. Sagi-Assif, B. Shalmon, C. Avivi, R. M. Pfeffer, I. P. Witz, and A. Ben-Baruch CXCL10 Promotes Invasion-Related Properties in Human Colorectal Carcinoma Cells Cancer Res., April 1, 2007; 67(7): 3396 - 3405. [Abstract] [Full Text] [PDF]